{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:36:01Z","timestamp":1761896161210},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.arteri.2015.07.002","type":"journal-article","created":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T06:11:17Z","timestamp":1441951877000},"page":"301-308","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Importancia de la dislipidemia en la enfermedad cardiovascular: un punto de vista"],"prefix":"10.1016","volume":"27","author":[{"given":"Juan F.","family":"Ascaso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Carmena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2015.07.002_bib0250","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2015.07.002_bib0255","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50mg\/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2015.07.002_bib0260","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/0300060513476428","article-title":"A review of statin use in patients with acute coronary syndrome in Western and Japanese populations","volume":"41","author":"Miyauchi","year":"2013","journal-title":"J Int Med Res."},{"key":"10.1016\/j.arteri.2015.07.002_bib0265","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"32","year":"2011","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2015.07.002_bib0270","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2015.07.002_bib0275","first-page":"127","article-title":"Comentarios del Comit\u00e9 Espa\u00f1ol Interdisciplinario de Prevenci\u00f3n Cardiovascular (CEIPC) a las Gu\u00edas Europeas de Prevenci\u00f3n Cardiovascular 2012","volume":"25","author":"Royo-Bordonada","year":"2013","journal-title":"Clin Invest Arterioscl."},{"key":"10.1016\/j.arteri.2015.07.002_bib0280","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2015.07.002_bib0285","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0021-9150(01)00410-5","article-title":"Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner","volume":"158","author":"Pedro-Botet","year":"2001","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2015.07.002_bib0290","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1194\/jlr.P800042-JLR200","article-title":"Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers","volume":"50","author":"Van Himbergen","year":"2009","journal-title":"JLR."},{"key":"10.1016\/j.arteri.2015.07.002_bib0295","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: Meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med."},{"key":"10.1016\/j.arteri.2015.07.002_bib0300","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0025-7753(04)75332-4","article-title":"Therapeutic compliance in the prevention of primary cardiovascular diseases with lovastatine. PRELOVAS study","volume":"123","author":"Mart\u00edn-Castillo","year":"2004","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.arteri.2015.07.002_bib0305","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","article-title":"Statin myopathy: A common dilemma not reflected in clinical trials","volume":"78","author":"Fernandez","year":"2011","journal-title":"Cleve Clin J Med."},{"key":"10.1016\/j.arteri.2015.07.002_bib0310","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jacc.2013.11.054","article-title":"Letter to the Editor: \u2018Should we forget about LDL cholesterol?\u2019","volume":"63","author":"Civeira","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2015.07.002_bib0315","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2015.07.002_bib0320","doi-asserted-by":"crossref","first-page":"E1189","DOI":"10.1503\/cmaj.101280","article-title":"Efficacy of statins for primary prevention in people at low cardiovascular risk: A meta-analysis","volume":"183","author":"Tonelli","year":"2011","journal-title":"CMAJ."},{"key":"10.1016\/j.arteri.2015.07.002_bib0325","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2015.07.002_bib0330","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.2014.10924","article-title":"Evaluation and treatment of older patients with hypercholesterolemia. A clinical review","volume":"312","author":"Stranderberg","year":"2014","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2015.07.002_bib0335","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.arteri.2015.07.002_bib0340","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.farma.2011.02.010","article-title":"Specific considerations on the prescription and therapeutic interchange of statins","volume":"36","author":"Garc\u00eda-Sabina","year":"2012","journal-title":"Farm Hosp."},{"key":"10.1016\/j.arteri.2015.07.002_bib0345","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jacl.2008.10.007","article-title":"Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases","volume":"2","author":"Ming","year":"2008","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2015.07.002_bib0350","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam Clin Pharmacol."},{"key":"10.1016\/j.arteri.2015.07.002_bib0355","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.beem.2013.11.006","article-title":"Lipid lowering in liver and chronic kidney disease","volume":"28","author":"Herrick","year":"2014","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"10.1016\/j.arteri.2015.07.002_bib0360","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MOL.0b013e32834b4994","article-title":"Statins and the risk of new-onset diabetes: A review of recent evidence","volume":"22","author":"Preiss","year":"2011","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.arteri.2015.07.002_bib0365","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2015.07.002_bib0370","first-page":"205","article-title":"Efectividad y satisfacci\u00f3n del tratamiento de la dislipidemia con pitavastatina. Estudio observacional, postautorizaci\u00f3n, descriptivo y multic\u00e9ntrico (estudio REINA)","volume":"26","author":"Rodr\u00edguez Arroyo","year":"2014","journal-title":"Clin Invest Arterioscl."},{"key":"10.1016\/j.arteri.2015.07.002_bib0375","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4103\/0976-500X.136097","article-title":"Statin induced diabetes and its clinical implications","volume":"5","author":"Aiman","year":"2014","journal-title":"J Pharmacol Pharmacother."},{"key":"10.1016\/j.arteri.2015.07.002_bib0380","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1093\/eurheartj\/ehq205","article-title":"How to calculate vascular age with the SCORE project scales: A new method of cardiovascular risk evaluation","volume":"31","author":"Cuende","year":"2010","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2015.07.002_bib0385","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia\u2014full report","volume":"8","year":"2014","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2015.07.002_bib0390","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00125-011-2336-9","article-title":"Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The Di@bet.es Study","volume":"55","author":"Soriguer","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.arteri.2015.07.002_bib0395","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0953-6205(03)00022-0","article-title":"Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population","volume":"14","author":"Ascaso","year":"2003","journal-title":"Eur J Intern Med."},{"issue":"Suppl B","key":"10.1016\/j.arteri.2015.07.002_bib0400","doi-asserted-by":"crossref","first-page":"85B","DOI":"10.1016\/S0828-282X(06)70992-8","article-title":"Metabolic syndrome: A marker of patients at high cardiovascular risk","volume":"22","author":"Lau","year":"2006","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.arteri.2015.07.002_bib0405","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00129784-200707010-00004","article-title":"Management of dyslipidemia in the metabolic syndrome: Recommendations of the Spanish HDL-Forum","volume":"7","author":"Ascaso","year":"2007","journal-title":"Am J Cardiovasc Drugs."},{"key":"10.1016\/j.arteri.2015.07.002_bib0410","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2015.07.002_bib0415","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4065\/mcp.2009.0517","article-title":"Using apolipoprotein B to manage dyslipidemic patients: Time for a change?","volume":"85","author":"Harper","year":"2010","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.arteri.2015.07.002_bib0420","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","article-title":"Clinical implications of discordance between low-density lipoprotein cholesterol and particle number","volume":"5","author":"Otvos","year":"2011","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2015.07.002_bib0425","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.arteri.2015.07.002_bib0430","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1742-1241.2012.02998.x","article-title":"Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population","volume":"67","author":"Martinez-Hervas","year":"2013","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.arteri.2015.07.002_bib0435","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.amjcard.2010.05.002","article-title":"Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control","volume":"106","author":"Carey","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arteri.2015.07.002_bib0440","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.07.002_bib0445","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1185\/03007995.2010.489341","article-title":"International Steering Committee of R3i. Implications of the ACCORD Lipid study: Perspective from the Residual Risk Reduction Initiative (R3i)","volume":"26","author":"Fruchart","year":"2010","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.arteri.2015.07.002_bib0450","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2015.07.002_bib0455","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"New Eng J Med."},{"issue":"10 Suppl","key":"10.1016\/j.arteri.2015.07.002_bib0460","doi-asserted-by":"crossref","first-page":"10E","DOI":"10.1016\/j.amjcard.2009.09.014","article-title":"Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial","volume":"104","author":"Barter","year":"2009","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.arteri.2015.07.002_bib0465","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.07.002_bib0470","doi-asserted-by":"crossref","first-page":"e94585","DOI":"10.1371\/journal.pone.0094585","article-title":"Effect of HDL-raising drugs on cardiovascular outcomes: A systematic review and meta-regression","volume":"9","author":"Kaur","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.arteri.2015.07.002_bib0475","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): A randomised, double-blind, placebo-controlled, phase3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2015.07.002_bib0480","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.07.002_bib0485","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nrcardio.2012.182","article-title":"HDL cholesterol studies \u2014 more of the same?","volume":"10","author":"Despr\u00e9s","year":"2013","journal-title":"Nat Rev Cardiol."},{"key":"10.1016\/j.arteri.2015.07.002_bib0490","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia. The LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916815001114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916815001114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T10:37:46Z","timestamp":1567161466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916815001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0214916815001114"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2015.07.002","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Importancia de la dislipidemia en la enfermedad cardiovascular: un punto de vista","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2015.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}